Adjuvant SOX chemotherapy versus concurrent chemoradiotherapy after D2 radical resection of locally advanced esophagogastric junction (EGJ) adenocarcinoma: study protocol for a randomized phase III trial (ARTEG)

被引：0

作者：

Jinwen Shen

Xiu Zhu

Yian Du

Yuan Zhu

Pengfei Yu

Litao Yang

Zhiyuan Xu

Ling Huang

Yunli Zhang

Yanqiang Zhang

Luying Liu

Xiangdong Cheng

机构：

[1] Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital),Department of Abdominal Radiotherapy

[2] Zhejiang Provincial Research Center for Cancer of Upper Gastrointestinal Tract,Department of Pathology

[3] Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital),Department of Abdominal Surgery

[4] Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital),undefined

来源：

Trials | / 22卷

关键词：

Esophagogastric junction adenocarcinoma; D2 radical resection; Adjuvant chemoradiotherapy;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[41] Adjuvant chemoradiotherapy versus adjuvant chemotherapy for patients with N3 gastric cancer after D2/R0 resection: a retrospective study based on propensity score analyses
Zhou, Meng-Long
Yang, Wang
Wang, Ya-Qi
Mo, Miao
Hu, Ran
Wang, Yan
Yang, Jia-Ning
Li, Gui-Chao
Wang, Ya-Nong
Zhang, Zhen
CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 4855 - 4870
[42] Overall survival of perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in locally advanced gastric or gastrooesophageal junction adenocarcinoma undergoing D2 gastrectomy: An updated analysis of RESOLVE trial
Zhang, X.
Li, Z.
Liang, H.
Xue, Y.
Wang, Y.
Zhou, Z.
Yu, J.
Chen, L.
Du, Y.
Li, G.
Xiao, G.
Wu, D.
Zhou, Y.
Dang, C.
He, Y.
Zhang, Z.
Sun, Y.
Li, Y.
Shen, L.
Ji, J.
ANNALS OF ONCOLOGY, 2023, 34 : S1318 - S1319
[43] Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial
Hong, Yong Sang
Nam, Byung-Ho
Kim, Kyu-pyo
Kim, Jeong Eun
Park, Seong Joon
Park, Young Suk
Park, Joon Oh
Kim, Sun Young
Kim, Tae-You
Kim, Jee Hyun
Ahn, Joong Bae
Lim, Seok-Byung
Yu, Chang Sik
Kim, Jin Cheon
Yun, Seong Hyeon
Kim, Jong Hoon
Park, Jin-hong
Park, Hee Chul
Jung, Kyung Hae
Kim, Tae Won
LANCET ONCOLOGY, 2014, 15 (11): : 1245 - 1253
[44] A comparison of concurrent chemoradiotherapy and radical surgery in patients with specific locally advanced cervical cancer (stage IB3, IIA2, IIICr): trial protocol for a randomized controlled study (C-CRAL trial)
Qiu, Junjun
Sun, Shugen
Liu, Qinqin
Fu, Jie
Huang, Yan
Hua, Keqin
JOURNAL OF GYNECOLOGIC ONCOLOGY, 2023, 34 (05)
[45] Oxaliplatin plus S-1 or capecitabine as neoadjuvant or adjuvant chemotherapy for locally advanced gastric cancer with D2 lymphadenectomy: 5-year follow-up results of a phase II-III randomized trial
Xue, Kan
Ying, Xiangji
Bu, Zhaode
Wu, Aiwen
Li, Zhongwu
Tang, Lei
Zhang, Lianhai
Zhang, Yan
Li, Ziyu
Ji, Jiafu
CHINESE JOURNAL OF CANCER RESEARCH, 2018, 30 (05) : 516 - +
[46] Maintenance tegafur-uracil versus observation following an adjuvant oxaliplatin-based regimen in patients with stage III colon cancer after radical resection: study protocol for a randomized controlled trial
Yeh, Yung-Sung
Tsai, Hsiang-Lin
Huang, Ching-Wen
Wei, Po-Li
Sung, Yung-Chuan
Tang, Hsiu-Chih
Wang, Jaw-Yuan
TRIALS, 2017, 18
[47] Maintenance tegafur-uracil versus observation following an adjuvant oxaliplatin-based regimen in patients with stage III colon cancer after radical resection: study protocol for a randomized controlled trial
Yung-Sung Yeh
Hsiang-Lin Tsai
Ching-Wen Huang
Po-Li Wei
Yung-Chuan Sung
Hsiu-Chih Tang
Jaw-Yuan Wang
Trials, 18
[48] Randomized phase II trial of CAPOX with continuous versus intermittent use of oxaliplatin as an adjuvant chemotherapy after curative resection of stage II/III colon cancer (CCOG-1302 study)
Nakamura, Masanori
Nakayama, Goro
Ishigure, Kiyoshi
Mashita, Naoki
Yokoyama, Hiroyuki
Hattori, Norifumi
Uehara, Keisuke
Yamada, Suguru
Koike, Masahiko
Kodera, Yasuhiro
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[49] Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE) final report of a randomised, open-label, phase 3 trial
Zhang, Xiaotian
Liang, Han
Li, Ziyu
Xue, Yingwei
Wang, Yanong
Zhou, Zhiwei
Yu, Jiren
Bu, Zhaode
Chen, Lin
Du, Yian
Wang, Xinbao
Wu, Aiwen
Li, Guoli
Su, Xiangqian
Xiao, Gang
Cui, Ming
Wu, Dan
Chen, Li
Wu, Xiaojiang
Zhou, Yanbing
Zhang, Lianhai
Dang, Chengxue
He, Yulong
Zhang, Zhongtao
Sun, Yihong
Li, Yong
Chen, Huanqiu
Bai, Yuxian
Wang, Yakun
Yu, Peiwu
Zhu, Guanbao
Suo, Jian
Jia, Baoqing
Li, Leping
Huang, Changming
Li, Fei
Ye, Yingjiang
Xu, Huimian
Wang, Xin
Yuan, Yannan
Jianyu, E.
Ying, Xiangji
Yao, Chen
Shen, Lin
Ji, Jiafu
LANCET ONCOLOGY, 2025, 26 (03): : 312 - 319
[50] Perioperative camrelizumab (C) combined with rivoceranib (R) and chemotherapy (chemo) versus chemo for locally advanced resectable gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The first interim analysis of a randomized, phase III trial (DRAGON IV)
Li, C.
Zheng, Y.
Shi, Z.
Yang, L.
Zhang, B.
Wang, Z.
Chen, H.
Wang, X.
Zhao, P.
Dong, J.
Lian, C.
Zhao, Q.
Zheng, Z.
Zhang, A.
Xu, S.
Wang, K.
Yuan, F.
Tian, Y.
Yin, K.
Zhu, Z.
ANNALS OF ONCOLOGY, 2023, 34 : S852 - S852

← 1 2 3 4 5 →